Drug Profile

NV 354

Alternative Names: NV-354

Latest Information Update: 22 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroVive Pharmaceutical
Developer Abliva
Class Succinates
Mechanism of Action Mitochondrial oxidative phosphorylation modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Mitochondrial disorders
New Molecular Entity No

Highest Development Phases

Preclinical Mitochondrial disorders

Most Recent Events

22 Jul 2025 NV 354 receives Orphan Drug status for Mitochondrial disorders in Europe (Abliva Pipeline, July 2025)
02 Jan 2024 NV 354 is still in preclinical trials for Mitochondrial disorders in Sweden (NeuroVive Pharmaceutical pipeline, January 2024)
28 Oct 2021 No recent reports of development identified for preclinical development in Mitochondrial disorders in Sweden (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com